Investigating a protein's role in brain tumors and their surrounding environment
Targeting extracellular signaling-regulated kinase 5 (ERK5) in brain tumors and their microenvironment
This study is looking at how a protein called ERK5 affects the growth of a serious brain tumor called DIPG, with the hope of finding new ways to help patients with this challenging condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10783789 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, ERK5, contributes to the growth of high-grade brain tumors, particularly a deadly type known as diffuse intrinsic pontine glioma (DIPG). The study will utilize advanced models to explore how ERK5 influences both the tumor cells and the immune cells in the brain that interact with these tumors. By examining these interactions, the researchers aim to uncover new therapeutic strategies that could improve treatment outcomes for patients with DIPG.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with high-grade gliomas, particularly those with DIPG.
Not a fit: Patients with brain tumors that do not involve the ERK5 pathway or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new treatments that specifically target the mechanisms driving the growth of brain tumors like DIPG.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways in other types of cancers, suggesting potential for success in this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Agnihotri, Sameer — University of Pittsburgh at Pittsburgh
- Study coordinator: Agnihotri, Sameer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.